Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24197466 | 0.89 | HTR1B (0.45) | HTR1BSLC6A4CTSLADRB2 | |
| SCHEMBL25569657 | 0.87 | SLC6A4 (0.46) | HTR1BSLC6A4CTSLADRB2 | |
| SCHEMBL25569651 | 0.82 | TAAR1 (0.47) | HTR1BSLC6A4 | |
| SCHEMBL25569516 | 0.80 | SLC6A4 (0.36) | SLC6A4SLC5A2CTSL | |
| SCHEMBL25569514 | 0.80 | SLC6A4 (0.36) | SLC6A4SLC5A2CTSL | |
| SCHEMBL25569515 | 0.80 | SLC6A4 (0.36) | SLC6A4SLC5A2CTSL | |
| SCHEMBL25569513 | 0.77 | SIGMAR1 (0.45) | SLC6A4CTSLADRB2 | |
| SCHEMBL14172986 | 0.76 | CTSL (0.46) | SLC6A4SLC5A2CTSL | |
| SCHEMBL24197473 | 0.76 | SLC6A4 (0.46) | HTR1BSLC6A4ADRB2 | |
| SCHEMBL25569277 | 0.76 | HTR1B (0.33) | HTR1BSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159487-A1 | ADVANTAGEOUS BENZOTHIOPHENE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | SLC6A3, CREBBP, SLC1A2 | HTR1B 511/4885SLC6A4 21/4885SLC5A2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.